Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

PubMed  Google Scholar 

He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021;11:3379–92.

PubMed  PubMed Central  Google Scholar 

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.

PubMed  Google Scholar 

Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789.

PubMed  PubMed Central  Google Scholar 

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5:546–50.

PubMed  Google Scholar 

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.

PubMed  Google Scholar 

Su R, Zhu J, Wu S, Luo H, He Y. Prognostic significance of platelet (PLT) and platelet to mean platelet volume (PLT/MPV) ratio during apatinib second-line or late-line treatment in advanced esophageal squamous cell carcinoma patients. Technol Cancer Res Treat. 2022;21:15330338211072974.

PubMed  PubMed Central  Google Scholar 

Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33:1760–9.

PubMed  Google Scholar 

Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506–28.

PubMed  Google Scholar 

Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H, et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014;74:840–51.

PubMed  Google Scholar 

Ren L, Fang X, Shrestha SM, Ji Q, Ye H, Liang Y, et al. LncRNA SNHG16 promotes development of oesophageal squamous cell carcinoma by interacting with EIF4A3 and modulating RhoU mRNA stability. Cell Mol Biol Lett. 2022;27:89.

PubMed  PubMed Central  Google Scholar 

Linder P, Jankowsky E. From unwinding to clamping - the DEAD box RNA helicase family. Nat Rev Mol Cell Biol. 2011;12:505–16.

PubMed  Google Scholar 

Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006;34:4206–15.

PubMed  PubMed Central  Google Scholar 

Hamm J, Lamond AI. Spliceosome assembly: the unwinding role of DEAD-box proteins. Curr Biol. 1998;8:R532–4.

PubMed  Google Scholar 

Linder P, Lasko PF, Ashburner M, Leroy P, Nielsen PJ, Nishi K, et al. Birth of the D-E-A-D box. Nature. 1989;337:121–2.

PubMed  Google Scholar 

Mo J, Liang H, Su C, Li P, Chen J, Zhang B. DDX3X: structure, physiologic functions and cancer. Mol Cancer. 2021;20:38.

PubMed  PubMed Central  Google Scholar 

Tauber D, Tauber G, Khong A, Van Treeck B, Pelletier J, Parker R. Modulation of RNA condensation by the DEAD-box protein eIF4A. Cell. 2020;180:411–26.e16.

PubMed  PubMed Central  Google Scholar 

Cai W, Xiong Chen Z, Rane G, Satendra Singh S, Choo Z, Wang C, et al. Wanted DEAD/H or alive: helicases winding up in cancers. J Natl Cancer Inst. 2017;109:djw278.

Tabassum S, Ghosh MK. DEAD-box RNA helicases with special reference to p68: unwinding their biology, versatility, and therapeutic opportunity in cancer. Genes Dis. 2023;10:1220–41.

PubMed  Google Scholar 

Xing Z, Ma WK, Tran EJ. The DDX5/Dbp2 subfamily of DEAD-box RNA helicases. Wiley Interdiscip Rev RNA. 2019;10:e1519.

PubMed  Google Scholar 

Terrone S, Valat J, Fontrodona N, Giraud G, Claude JB, Combe E, et al. RNA helicase-dependent gene looping impacts messenger RNA processing. Nucleic Acids Res. 2022;50:9226–46.

PubMed  PubMed Central  Google Scholar 

Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS, Stillman B. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov. 2012;2:812–25.

PubMed  PubMed Central  Google Scholar 

Mersaoui SY, Yu Z, Coulombe Y, Karam M, Busatto FF, Masson JY, et al. Arginine methylation of the DDX5 helicase RGG/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids. EMBO J. 2019;38:e100986.

PubMed  PubMed Central  Google Scholar 

Saporita AJ, Chang HC, Winkeler CL, Apicelli AJ, Kladney RD, Wang J, et al. RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis. Cancer Res. 2011;71:6708–17.

PubMed  PubMed Central  Google Scholar 

Mani S, Yan B, Cui Z, Sun J, Utturkar S, Foca A, et al. Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. Theranostics. 2020;10:10957–72.

PubMed  PubMed Central  Google Scholar 

Nicol SM, Bray SE, Black HD, Lorimore SA, Wright EG, Lane DP, et al. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage. Oncogene. 2013;32:3461–9.

PubMed  Google Scholar 

Legrand J, Chan AL, La HM, Rossello FJ, Änkö ML, Fuller-Pace FV, et al. DDX5 plays essential transcriptional and post-transcriptional roles in the maintenance and function of spermatogonia. Nat Commun. 2019;10:2278.

PubMed  PubMed Central  Google Scholar 

Nyamao RM, Wu J, Yu L, Xiao X, Zhang FM. Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies. Biochim Biophys Acta Rev Cancer. 2019;1871:85–98.

PubMed  Google Scholar 

Ma L, Zhao X, Wang S, Zheng Y, Yang S, Hou Y, et al. Decreased expression of DEAD-Box helicase 5 inhibits esophageal squamous cell carcinomas by regulating endoplasmic reticulum stress and autophagy. Biochem Biophys Res Commun. 2020;533:1449–56.

PubMed  Google Scholar 

Su HF, Shaker S, Kuang Y, Zhang M, Ye M, Qiao X. Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix). Med Res Rev. 2021;41:1999–2038.

PubMed  Google Scholar 

Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28:1275–83.

PubMed  Google Scholar 

Aobulikasimu N, Zheng D, Guan P, Xu L, Liu B, Li M, et al. The anti-inflammatory effects of isoflavonoids from radix astragali in hepatoprotective potential against LPS/D-gal-induced acute liver injury. Planta Med. 2023;89:385–96.

PubMed  Google Scholar 

Bratkov VM, Shkondrov AM, Zdraveva PK, Krasteva IN. Flavonoids from the genus astragalus: phytochemistry and biological activity. Pharmacogn Rev. 2016;10:11–32.

PubMed  PubMed Central  Google Scholar 

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014;16:R53.

PubMed  PubMed Central  Google Scholar 

Lin KT, Gong J, Li CF, Jang TH, Chen WL, Chen HJ, et al. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. Cancer Res. 2012;72:3000–9.

PubMed  Google Scholar 

Uen YH, Fang CL, Hseu YC, Shen PC, Yang HL, Wen KS, et al. VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization. Sci Rep. 2015;5:9360.

PubMed  PubMed Central  Google Scholar 

Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30.

PubMed  Google Scholar 

Xie M, Ma T, Xue J, Ma H, Sun M, Zhang Z, et al. The long intergenic non-protein coding RNA 707 promotes proliferation and metastasis of gastric cancer by interacting with mRNA stabilizing protein HuR. Cancer Lett. 2019;443:67–79.

PubMed  Google Scholar 

Nayak RC, Chang KH, Singh AK, Kotliar M, Desai M, Wellendorf AM, et al. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nat Commun. 2022;13:3056.

PubMed  PubMed Central  Google Scholar 

Chen Z, Chen X, Lu B, Gu Y, Chen Q, Lei T, et al. Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. J Hematol Oncol. 2020;13:7.

PubMed  PubMed Central  Google Scholar 

Tan B, Li Y, Zhao Q, Fan L, Liu Y, Wang D, et al. Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway. Cancer Gene Ther. 2014;21:526–31.

PubMed  Google Scholar 

Nomura T, Yamasaki M, Hirai K, Inoue T, Sato R, Matsuura K, et al. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia. Mol Cancer. 2013;12:27.